MEPROBAMATE AND ASPIRIN
Clinical safety rating: avoid
Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.
Meprobamate is a carbamate derivative that acts as a CNS depressant, potentiating GABA-A receptor activity and inhibiting polysynaptic spinal reflexes. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
| Metabolism | Meprobamate: Hepatic metabolism via CYP2C19 and other CYP450 enzymes to inactive hydroxylated metabolites, followed by glucuronidation. Aspirin: Hydrolyzed by esterases to salicylic acid; salicylic acid undergoes conjugation with glycine (salicyluric acid) and glucuronic acid, and oxidation to gentisic acid. |
| Excretion | Aspirin: Renal excretion of salicylates (75% as salicyluric acid, 10% as salicylic acid, 10% as phenolic glucuronide, 5% as acyl glucuronide). Meprobamate: Renal excretion (10-20% unchanged, 80-90% as hydroxylated metabolites) and biliary excretion (<5%). |
| Half-life | Aspirin: 15-20 minutes (parent drug), but salicylate half-life is dose-dependent: 2-3 hours for low doses, 15-30 hours for high doses. Meprobamate: 6-17 hours (mean 10 hours), prolonged in overdose or hepatic impairment. |
| Protein binding | Aspirin: 80-90% bound to albumin (dose-dependent, saturable). Meprobamate: 15-25% bound to albumin. |
| Volume of Distribution | Aspirin: 0.1-0.2 L/kg for salicylate. Meprobamate: 0.7-0.8 L/kg. |
| Bioavailability | Aspirin: Oral: 50-75% (dose-dependent, due to first-pass hydrolysis). Meprobamate: Oral: >90%. |
| Onset of Action | Aspirin: Oral: 5-30 minutes (analgesic, antipyretic); 1-2 hours (antiplatelet). Meprobamate: Oral: 30-60 minutes (sedative, anxiolytic). |
| Duration of Action | Aspirin: Analgesic/antipyretic: 4-6 hours; antiplatelet: 7-10 days (irreversible COX-1 inhibition). Meprobamate: 4-6 hours (sedation), longer with higher doses. |
Aspirin 325 mg and meprobamate 200 mg orally every 6 to 8 hours as needed for pain or anxiety. Maximum daily dose: aspirin 3.9 g, meprobamate 1.6 g.
| Dosage form | TABLET |
| Renal impairment | Aspirin: CrCl <10 mL/min: avoid use. Meprobamate: GFR 10-50 mL/min: administer every 9-12 hours; GFR <10 mL/min: administer every 12-18 hours. |
| Liver impairment | Aspirin: Child-Pugh Class C: avoid use. Meprobamate: Child-Pugh Class B: reduce dose by 50%; Class C: avoid use. |
| Pediatric use | Not recommended due to aspirin's association with Reye's syndrome in children with viral infections. |
| Geriatric use | Start with lowest effective dose. Aspirin: increased bleeding risk; monitor renal function. Meprobamate: initial dose 200 mg twice daily due to increased sensitivity and risk of sedation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Anticoagulants like warfarin increase bleeding risk Concomitant use with other NSAIDs increases GI toxicity Risk of Reye's syndrome in children and teenagers with viral infections.
| FDA category | Positive |
| Breastfeeding | Meprobamate: Excreted into breast milk at concentrations 2–4 times maternal plasma; M/P ratio approximately 2.5. Infant serum levels can reach therapeutic levels. Effect on nursing infant is unknown; use caution. Aspirin: Excreted into breast milk in low amounts (M/P ratio 0.03–0.3); however, high maternal doses may cause adverse effects in infant (e.g., platelet dysfunction, Reye's syndrome risk with viral illness). Consider alternative analgesics. |
■ FDA Black Box Warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS – Aspirin increases risk of GI bleeding; meprobamate may cause dependence and withdrawal seizures.
| Common Effects | fever |
| Serious Effects |
["Hypersensitivity to meprobamate, aspirin, or NSAIDs","Active peptic ulcer or GI bleeding","Severe hepatic or renal impairment","Children < 12 years with viral infection (risk of Reye's syndrome)","Third trimester of pregnancy (aspirin associated risk)","History of bronchospasm or allergic reaction with NSAIDs"]
| Precautions | ["Risk of GI bleeding and ulceration (aspirin related) – use lowest effective dose","Central nervous system depression – avoid alcohol and other CNS depressants","Dependence and withdrawal reactions (meprobamate) – may cause seizures after discontinuation","May mask signs of infection or inflammation","Use with caution in patients with hepatic or renal impairment, bleeding disorders, history of peptic ulcer","Not recommended in pregnancy (risk of fetal harm, premature closure of ductus arteriosus)"] |
Loading safety data…
| Teratogenic Risk | First trimester: Meprobamate is associated with an increased risk of congenital malformations, particularly cardiovascular defects, when used during first trimester. Aspirin at high doses (≥325 mg/day) may increase risk of gastroschisis and intracranial hemorrhage. Second trimester: Aspirin at high doses may increase risk of intrauterine growth restriction (IUGR). Third trimester: Aspirin at high doses may cause premature closure of ductus arteriosus, oligohydramnios, and impaired platelet function in neonate. Meprobamate may cause neonatal withdrawal syndrome with chronic use. Both drugs cross the placenta. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and signs of bleeding. Fetal ultrasound for growth and amniotic fluid volume. In third trimester, monitor ductus arteriosus via echocardiography if high-dose aspirin used. Neonatal monitoring for signs of meprobamate withdrawal or aspirin-related bleeding. |
| Fertility Effects | Aspirin may inhibit ovulation by suppressing prostaglandin synthesis; reversible on discontinuation. Meprobamate may cause menstrual irregularities at high doses. No definitive evidence of long-term fertility impairment. |